GlassScriptPhysician profile
Quinn Cotilla
NPI 1518555127
$2,281.90
in general payments reported to CMS, 2019-2025
23 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $737 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.98 | 2023-2025 | Qulipta, Vraylar, Liletta |
| Astrazeneca Pharmaceuticals LP | $340.92 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $280.50 | 2023-2025 | Rexulti |
| Indivior INC. | $269.03 | 2024-2025 | Sublocade |
| Pfizer INC. | $169.35 | 2023-2025 | |
| Novo Nordisk INC | $162.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $139.50 | 2023-2024 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $79.52 | 2024-2025 | Accrufer |
| Exact Sciences Corporation | $70.17 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tempus Ai, INC | $53.61 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.59 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $40.70 | 2023 | |
| Antares Pharma, INC. | $36.47 | 2024-2025 | Xyosted |
| Hologic Sales and Service, LLC | $25.60 | 2023 | Aptima, Thinprep 2000 Processor |
| Csl Behring | $25.16 | 2025 | Hizentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $24.55 | 2024 | Immunocap |
| Strata Skin Sciences, INC. | $21.26 | 2025 | Xtrac |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.15 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $18.73 | 2023 | Quviviq |
| Organon LLC | $18.30 | 2023 | Nexplanon |
| Halozyme INC | $18.22 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.71 | 2024 | Voquezna |
| Fidia Pharma USA INC. | $13.30 | 2023 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quinn Cotilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.